Fluticasone propionate/salmeterol (Advair HFA) vs Vilanterol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
Fluticasone propionate/salmeterol (Advair HFA)
Marketed by GlaxoSmithKline
NCT00448435 · Phase 3 · completed
The 51 participants were randomized to treatment sequences and received an active comparator, but the trial was not blinded. Its primary morning PEF endpoint met the prespecified equivalence margin, while the endpoint was a physiologic surrogate rather than a hard clinical or endoscopic measure, supporting a moderate evidence grade.
Reported efficacy
Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods (Crossover Period Weeks 1-4, and 7-10): Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods (Crossover Period Weeks 1-4, and 7-10): SFC 50/100 Mcg/Day 14.3 Liters/minute (Standard Error 4.53) vs SLM 50 Mcg + FP 100 Mcg/Day 17.1 Liters/minute (Standard Error 4.53) (met)
Result source: NCT00448435
Vilanterol
Developed by GlaxoSmithKline
NCT00381667 · Phase 2 · completed
The study was randomized, double-blind, and placebo-controlled, but enrolled only 14 participants. Its primary outcomes included lung-function and safety measurements rather than a hard clinical endpoint, and the primary comparison cannot be assessed because results have not been posted.
Reported efficacy
Mean Change From Baseline in Clinic Visit Trough FEV1 at Day 28 (Last Observation Carried Forward [LOCF]) (Baseline and Day 28): Mean Change From Baseline in Clinic Visit Trough FEV1 at Day 28 (Last Observation Carried Forward [LOCF]) (Baseline and Day 28): GW642444M 3 µg 0.212 Liters (Standard Error 0.036) | GW642444M 6.25 µg 0.217 Liters (Standard Error 0.035) | GW642444M 12.5 µg 0.278 Liters (Standard Error 0.036) | GW642444M 25 µg 0.269 Liters (Standard Error 0.035) | GW642444M 50 µg 0.309 Liters (Standard Error 0.035) vs Placebo 0.147 Liters (Standard Error 0.036) (mixed)
Result source: NCT00600171
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Fluticasone propionate/salmeterol (Advair HFA) | Vilanterol |
|---|---|---|
| Severe exacerbations, annualised rate | 1.9 vs 2.1vs Fluticasone PropionateNCT00452699 | —Not reported |
| Trough FEV1, change | —Not posted · NCT00646620 | 0.3 vs 0.1+0.1 vs placeboNCT006001718 other results
|
| ACQ-5, change | —Not posted · NCT00646620 | —Not reported |
| OCS dose reduction | —Not posted · NCT00646620 | —Not reported |
Severe exacerbations, annualised rate
- Fluticasone propionate/salmeterol (Advair HFA)
- 1.9 vs 2.1vs Fluticasone PropionateNCT00452699
- Vilanterol
- —Not reported
Trough FEV1, change
- Fluticasone propionate/salmeterol (Advair HFA)
- —Not posted · NCT00646620
- Vilanterol
- 0.3 vs 0.1+0.1 vs placeboNCT00600171
8 other results
- 0.3 vs 0.1 NCT00600171
- 0.3 vs 0.1 NCT00600171
- 0.2 vs 0.1 NCT00600171
- 0.2 vs 0.1 NCT00600171
- -0.5 vs -0.8 NCT01128569
- 0.2 vs 0.2 NCT01573767
- 0.2 vs 0.2 NCT01573767
- 0.2 vs 0.2 NCT01573767
ACQ-5, change
- Fluticasone propionate/salmeterol (Advair HFA)
- —Not posted · NCT00646620
- Vilanterol
- —Not reported
OCS dose reduction
- Fluticasone propionate/salmeterol (Advair HFA)
- —Not posted · NCT00646620
- Vilanterol
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. Fluticasone propionate/salmeterol (Advair HFA): 5 of 5 rows · Vilanterol: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Fluticasone propionate/salmeterol (Advair HFA) | Vilanterol |
|---|---|---|
| FEV1 absolute change · L | 0.2 vs 0.09 Fluticasone Propionate L @ 52wk250/50 mcg BIDa,b,c,d NCT00452699 · Phase 4 · registry result, not featured evidence | -0.227 vs -0.372 placebo L @ 4.14wk100/25 µg ODa,b,c,d NCT01128569 · Phase 2 · registry result, not featured evidence |
| Dropout rate | —50/100 mcg/daye NCT00448435 · Phase 3 · Asthma · phase 3 show 3 more results—50/100 mcg/day NCT00448435 · Phase 3 · Asthma · phase 3 26.5%250/50 mcg BID NCT00452699 · Phase 4 · registry result, not featured evidence 0% NCT00449046 · Phase 3 · registry result, not featured evidence | 7.9%25 µgf NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 show 16 more results4.9%50 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 12%12.5 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 9.9%6.25 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 16.8%3 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 12.2%25 µg OD NCT01181895 · Phase 3 · registry result, not featured evidence 21.1%25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 12.4%12.5 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 18.4%6.25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence —12.5 OD NCT01573767 · Phase 2 · registry result, not featured evidence —25 OD NCT01573767 · Phase 2 · registry result, not featured evidence —6.25 OD NCT01573767 · Phase 2 · registry result, not featured evidence —100/25 µg AM NCT01287065 · Phase 2 · registry result, not featured evidence —100/25 µg PM NCT01287065 · Phase 2 · registry result, not featured evidence —100/25 µg OD NCT01128595 · Phase 2 · registry result, not featured evidence —25 µg NCT01453296 · Phase 2 · registry result, not featured evidence —100/25 µg OD NCT01128569 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —50/100 mcg/daye NCT00448435 · Phase 3 · Asthma · phase 3 show 3 more results—50/100 mcg/day NCT00448435 · Phase 3 · Asthma · phase 3 3.3%250/50 mcg BID NCT00452699 · Phase 4 · registry result, not featured evidence — NCT00449046 · Phase 3 · registry result, not featured evidence | 1%25 µgf NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 show 16 more results0%50 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0%12.5 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0%6.25 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 1%3 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0.9%25 µg OD NCT01181895 · Phase 3 · registry result, not featured evidence 0.9%25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 0%12.5 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 0.9%6.25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence —12.5 OD NCT01573767 · Phase 2 · registry result, not featured evidence —25 OD NCT01573767 · Phase 2 · registry result, not featured evidence —6.25 OD NCT01573767 · Phase 2 · registry result, not featured evidence —100/25 µg AM NCT01287065 · Phase 2 · registry result, not featured evidence —100/25 µg PM NCT01287065 · Phase 2 · registry result, not featured evidence —100/25 µg OD NCT01128595 · Phase 2 · registry result, not featured evidence —25 µg NCT01453296 · Phase 2 · registry result, not featured evidence —100/25 µg OD NCT01128569 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%50/100 mcg/daye NCT00448435 · Phase 3 · Asthma · phase 3 show 3 more results0%50/100 mcg/day NCT00448435 · Phase 3 · Asthma · phase 3 4.6%250/50 mcg BID NCT00452699 · Phase 4 · registry result, not featured evidence — NCT00449046 · Phase 3 · registry result, not featured evidence | 0%25 µgf NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 show 16 more results0%50 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0%12.5 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0%6.25 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0%3 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0.9%25 µg OD NCT01181895 · Phase 3 · registry result, not featured evidence —25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence —12.5 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence —6.25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 0%12.5 OD NCT01573767 · Phase 2 · registry result, not featured evidence 0.9%25 OD NCT01573767 · Phase 2 · registry result, not featured evidence 0%6.25 OD NCT01573767 · Phase 2 · registry result, not featured evidence 0%100/25 µg AM NCT01287065 · Phase 2 · registry result, not featured evidence 0%100/25 µg PM NCT01287065 · Phase 2 · registry result, not featured evidence 0%100/25 µg OD NCT01128595 · Phase 2 · registry result, not featured evidence 0%25 µg NCT01453296 · Phase 2 · registry result, not featured evidence 0%100/25 µg OD NCT01128569 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 50/100 mcg/daye upper respiratory tract inflammation 13.7% nasopharyngitis 3.9% stomatitis 3.9% NCT00448435 · Phase 3 · Asthma · phase 3 show 3 more results50/100 mcg/day upper respiratory tract inflammation 34% gastroenteritis 14% nasopharyngitis 14% NCT00448435 · Phase 3 · Asthma · phase 3 250/50 mcg BID upper respiratory tract infection 20.3% headache 18.3% nasopharyngitis 17.6% NCT00452699 · Phase 4 · registry result, not featured evidence asthma 20% bronchitis 20% laryngopharyngitis 20% NCT00449046 · Phase 3 · registry result, not featured evidence | 25 µgf headache 6.9% (placebo 7.8%) upper respiratory tract infection 2% (placebo 2%) nasopharyngitis 0% (placebo 3.9%) NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 show 13 more results50 µg headache 7.8% (placebo 7.8%) nasopharyngitis 2% (placebo 3.9%) upper respiratory tract infection 2% (placebo 2%) NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 12.5 µg headache 9% (placebo 7.8%) upper respiratory tract infection 3% (placebo 2%) nasopharyngitis 0% (placebo 3.9%) NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 6.25 µg headache 6.9% (placebo 7.8%) nasopharyngitis 2% (placebo 3.9%) upper respiratory tract infection 1% (placebo 2%) NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 3 µg headache 11.9% (placebo 7.8%) nasopharyngitis 2% (placebo 3.9%) upper respiratory tract infection 2% (placebo 2%) NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 25 µg OD headache 8.7% (placebo 4.3%) nasopharyngitis 7.8% (placebo 10.3%) oropharyngeal pain 5.2% (placebo 6%) NCT01181895 · Phase 3 · registry result, not featured evidence 12.5 OD nasopharyngitis 8.8% (placebo 7%) headache 1.8% (placebo 3.5%) influenza 0% (placebo 0%) NCT01573767 · Phase 2 · registry result, not featured evidence 25 OD nasopharyngitis 7.9% (placebo 7%) headache 1.8% (placebo 3.5%) influenza 0% (placebo 0%) NCT01573767 · Phase 2 · registry result, not featured evidence 6.25 OD nasopharyngitis 7% (placebo 7%) headache 5.3% (placebo 3.5%) influenza 3.5% (placebo 0%) NCT01573767 · Phase 2 · registry result, not featured evidence 100/25 µg AM headache 25% (placebo 26.1%) nasopharyngitis 12.5% (placebo 13%) dysmenorrhoea 4.2% (placebo 0%) NCT01287065 · Phase 2 · registry result, not featured evidence 100/25 µg PM headache 32% (placebo 26.1%) gastroenteritis 8% (placebo 0%) nasopharyngitis 8% (placebo 13%) NCT01287065 · Phase 2 · registry result, not featured evidence 100/25 µg OD headache 55.6% (placebo 40.7%) nasopharyngitis 11.1% (placebo 7.4%) oropharyngeal pain 11.1% (placebo 7.4%) NCT01128595 · Phase 2 · registry result, not featured evidence 25 µg upper respiratory tract infection 11.1% (placebo 0%) headache 7.4% (placebo 7.7%) pyrexia 7.4% (placebo 0%) NCT01453296 · Phase 2 · registry result, not featured evidence 100/25 µg OD headache 9.8% (placebo 17.6%) dysphonia 3.9% (placebo 0%) mouth ulceration 3.9% (placebo 0%) NCT01128569 · Phase 2 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 2 versus Phase 4.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 4.14 weeks versus 52 weeks.
- ePopulation comparability has not been reviewed for 2 of these studies.
- fPopulation comparability has not been reviewed for 12 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Fluticasone propionate/salmeterol (Advair HFA)
+ 11 further endpoints in the CSV export.
Vilanterol
show 8 more results
show 9 more results
show 5 more results
show 5 more results
show 4 more results
show 4 more results
show 2 more results
show 3 more results
show 3 more results
show 5 more results
show 5 more results
+ 8 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fluticasone propionate/salmeterol (Advair HFA)'s landscape · Vilanterol's landscape